Special Issue

Multicomponent Nanomedicines for Photodynamic Diagnosis and Photodynamic Therapy

Message from the Guest Editors

Even though different drug discovery studies are composed of a single chemical entity, most analysts believe that "the one drug to fit all" approach will be unsustainable in the future as many diseases are multifactorial in nature and individual molecular targets cannot usually combat multifactorial diseases wherein multiple tissues or cell types are affected. Therefore, multi-drug or multi-target therapies are considered to be advantageous for multifactorial diseases. Our focus of this Special Issue is on multicomponent targeting drug delivery for photodynamic diagnosis (PDD) and photodynamic therapy (PDT) of oncological diseases. In addition, nanotechnology integrated with PDD and PDT strategies is a promising approach for the diagnosis and treatment of accurate lesions. In this regard, this Special Issue aims to publish high-quality research papers and reviews focusing on the design of smart nanomedicines in the PDD and PDT of various oncological tumors.

Guest Editors

Prof. Dr. Heidi Abrahamse

Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Johannesburg 2028, South Africa

Dr. Hanieh Montaseri

St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London SE1 9RT, UK

Deadline for manuscript submissions

closed (31 October 2024)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/183460

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

